In Brief: Glaxo
This article was originally published in The Tan Sheet
Executive Summary
Glaxo: Supplementary NDA for use of Flonase nasal spray in children ages 4-11 for treatment of seasonal and perennial allergic rhinitis filed Oct. 31, the company announces Dec. 5. Flonase (fluticasone propionate), an Rx product that is a potential candidate for OTC switch, is a once-a-day spray indicated for treatment of seasonal and perennial nasal allergies in patients 12 and older, the company says, adding that the product is not yet indicated for treatment of allergic rhinitis...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning